INDO-BANGLA PHARMACEUTICALS LTD STATEMENT OF FINANCIAL POSITION (Un-Audited) As at 31 March 2021

		Amounts in Taka	
Particulars	Notes	31st Mar,2021	30th June,2020
ASSETS:	9 1		w = -1
Non-current Assets:		1,263,176,525	1,126,809,674
Property, Plant and Equipment	3.00	1,218,061,075	1,061,759,460
Capital Work In Progress	4.00	45,115,450	65,050,214
Current Assets:		659,527,880	612,456,404
Inventories	5.00	194,652,643	190,289,732
Trade & Other Receivables	6.00	238,338,489	226,078,126
Advance, Deposits and Prepayments	7.00	216,980,018	182,249,756
Cash and Cash equivalents	8.00	9,556,730	13,838,790
TOTAL ASSETS		1,922,704,405	1,739,266,078
EQUITY AND LIABILITIES			
Shareholders' Equity:		1,580,188,139	1,517,598,176
Share Capital	9.00	1,137,371,400	1,115,070,000
Retained Earnings	10.00	442,816,739	402,528,176
NON-CURRENT LIABILITIES		116,784,552	94,720,685
Deferred Tax Liability	11.00	116,784,552	94,720,685
		· · · · · · · · · · · · · · · · · · ·	
Current Liabilities:		225,731,714	126,947,217
Short Term Loan	12.00	84,905,000	-
Provision for WPPF	13.00	16,819,541	10,850,277
Trade Payables	14.00	589,929	371,989
Provision for Taxes	15.00	115,593,611	107,770,381
Liabilities for Expenses	16.00	7,823,633	7,954,570
TOTAL OWNER'S EQUITY AND LIABILITIES		1,922,704,405	1,739,266,078
Net Asset Value (NAV) Per Share	25.00	13.89	13.61
Chief Financial Officer Company Secretary Di	rector	Managing Director	Aziza 230 Chairman 230
Place: Dhaka			

Place: Dhaka Dated: 29 April, 2021

INDO-BANGLA PHARMACEUTICALS LTD

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)

Amounts in Taka Particulars Notes 1st July 2020 to 31st 1st July 2019 to 1st Jan 2021 to 1st Janu 2020 to March,2021 31st March,2020 31st March,2021 31st March,2020 Net Sales Revenue 17.00 598,286,013 676,667,643 179,001,261 233,885,122 Less: Cost of Sales 18.00 385,191,402 401,140,524 131,753,213 141,559,079 **Gross Profit** 213,094,611 275,527,120 47,248,048 92,326,043 Less: Operating Expenses: 88,147,879 80,454,529 27,429,067 27,522,579 Administrative Expenses 19.00 27,863,292 24,807,675 9,718,097 9,566,159 **Financial Expenses** 20.00 2,563,461 1,462,375 Selling & Distributing Expenses 21.00 57,721,126 16,248,595 55,646,854 17,956,420 **Profit from Operations** 124,946,732 195,072,590 19,818,980 64,803,464 Add: Non Operating Income: 22.00 407,800 1,937,428 Profit before Contribution to WPPF & Welfare Fund 125,354,532 197,010,018 19,818,981 64,803,464 Less: Contribution to WPPF & Welfare Fund 13.00 5,969,263 9,381,429 943,761 3,085,879 Profit before Tax 119,385,268 187,628,589 18,875,220 61,717,584 Less: Income Tax Expenses: 29,887,097 47,100,890 4,718,805 14,491,554 Current Tax 29,283,722 23.00 7,823,229 (3,740,085) 9,527,050 Deferred Tax 11.00 22,063,868 17,817,168 8,458,890 4,964,504 Net Profit for the period 89,498,171 140,527,699 14,156,415 47,226,030 Basic Earnings per share (EPS) 24.00 0.79 1.24 0.12 0.42

For the Third quarter ended 31 March 2021

thief Finandial Officer

Company Secretary

Director

HUNCON Managing Director

iza Yearnin

Place: Dhaka Dated: 29 April, 2021

INDO BANGLA PHARMACEUTICALS LTD

Statement Of Changes In Equity (Un-Audited) For the Third quarter ended 31 March 2021

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2020	1,115,070,000	402,528,176	1,517,598,176
Issue of share Capital (Bonus)	22,301,400	(22,301,400)	
Cash Dividend	-	(26,908,208)	(26,908,208)
Net Profit for the period	-	89,498,171	89,498,171
Balance as at 31-03-2021	1,137,371,400	442,816,739	1,580,188,139

INDO BANGLA PHARMACEUTICALS LTD

Statement Of Changes In Equity (Un-Audited) For the Third quarter ended 31 March 2020

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 01-07-2019	1,023,000,000	351,627,332	1,374,627,332
Issue of share Capital (Bonus)	92,070,000	(92,070,000)	- -
Cash Dividend	-	(13,272,820)	(13,272,820)
Net Profit for the period		140,527,699	140,527,699
Balance as at 31-03-2020	1,115,070,000	386,812,211	1,501,882,211

Chief Financial Officer Company Secretary

Director

Managing Director

Chairman

Place: Dhaka Dated: 29 April, 2021

INDOBANGLA PHARMACEUTICALS LIMITED

Statement Of Cash Flows (Un-Audited)

For the Period ended 31 March, 2021

Particulars	Notes	Amounts in Taka	
		31 March, 2021	31 March, 2020
Cash Flow from Operating Activities			
Cash receipts from customers		586,025,650	620,397,850
Cash receipts from others income		407,800	3,175,236
Cash payment to Suppliers		(352,789,316)	(363,379,758)
Cash payment to Employees		(67,720,710)	(59,201,824)
Cash payment to Others	×	(43,678,094)	(34,568,022)
Cash Generate from operation		122,245,330	166,423,483
Cash payment against income Tax		(26,665,408)	(19,872,243)
Net Cash from Operating Activities	27.00	95,579,922	146,551,240
Cash Flow from Investing Activities			
acquisition of property, plant and equipment		(157,858,775)	(132,455,940)
aid for Work In Progress		-	(75,005,726)
dvance paid for L/C Margin Machinary	_	_	(23,024,564)
let Cash used in Investing Activities	-	(157,858,775)	(230,486,230)
ash Flow from Financing Activities			
hort Term Loan	Γ	144,746,500	· •
ettlement amount		(59,841,499)	-
ash payment to dividend		(26,908,208)	(13,272,820)
et Cash from Financing Activities	_	57,996,793	(13,272,820)
let increase in Cash and Cash equivalents		(4,282,060).	(97,207,810)
ash and Cash equivalents at beginning of the period		13,838,790	160,581,427
Cash and Cash Equivalent at end of the Period	-	9,556,730	63,373,617
let Operating Cash Flows Per Share (NOCFPS)	26.00	0.84	1.29
hief Financial Officer Company Secretary Director	or M	Anaging Director	Aziga year

Place: Dhaka Dated: 29 April, 2021